• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Foghorn Therapeutics Inc (NQ: FHTX )

8.300 +0.680 (+8.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 66,713
Open 7.760
Bid (Size) 8.020 (1)
Ask (Size) 8.400 (5)
Prev. Close 7.620
Today's Range 7.754 - 8.300
52wk Range 2.700 - 10.25
Shares Outstanding 36,936,886
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
October 10, 2024
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Participate in the BMO Oncology Summit
October 01, 2024
From Foghorn Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+28.68%
+28.68%
1 Month
+6.00%
+6.00%
3 Month
+48.48%
+48.48%
6 Month
+42.37%
+42.37%
1 Year
+138.85%
+138.85%

More News

Read More
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
September 03, 2024
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics: Q4 Earnings Insights
March 07, 2024
Via Benzinga
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
August 28, 2024
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
August 19, 2024
Via Benzinga
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
August 19, 2024
Via Benzinga
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
Via InvestorPlace
Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
August 08, 2024
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
May 28, 2024
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
May 22, 2024
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
May 20, 2024
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 06, 2024
Via InvestorPlace
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
May 06, 2024
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
April 16, 2024
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
April 09, 2024
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
April 05, 2024
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
March 26, 2024
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q4 2023
March 07, 2024
Via InvestorPlace
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
March 07, 2024
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
March 05, 2024
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
February 28, 2024
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
February 08, 2024
Via Benzinga
Why Foghorn Therapeutics (FHTX) Stock Is Exploding Higher
February 08, 2024
Via Benzinga
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
February 08, 2024
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap